Cardiorenal effects of newer antidiabetic agents Athanasia K. Papazafiropoulou, Elias Georgopoulos, Stavros Antonopoulos
Evaluation of Different Scores to Predict Non-alcoholic Fatty Liver Disease in patients with type 2 diabetes Angeliki M Angelidi, Athanasia Papazafiropoulou, Eleni-Margarita Tzouganatou, Konstantina Anagnostopoulou, Vasilis Velissaris, Vangelis Markakis, Ekaterini Vagena, Αndreas Melidonis
The cardioprotective effects of flavonoids: a focus on classic cardiovascular risk factors Eleni Kokkou, Nikoleta Bozini, Maria Lavda, Konstantinos Mourouzis, Gerasimos Siasos
Lipid control in patients with and without type 2 Diabetes Mellitus (T2DM). The experience of a special unit of a second grade hospital Stamatis S Papadatos, Adamantios Bourdakis
Naltrexone ER/Bupropion ER for the treatment of obesity Eleni Pappa, Theodosios D Filippatos, Moses S Elisaf
SGLT2 inhibitors: what to expect in the future Α. Liontos, E. Klouras, M. Florentin, E. Liberopoulos, M. Elisaf
The use of dapagliflozin in the treatment of type 2 diabetes mellitus Α. Liontos, E. Klouras, M. Florentin, E. Liberopoulos, M. Elisaf
Cardiovascular risk factors and longevity M. Kouris, A. Konstantinou, M. Kouri, A. Stavrou, E. Bilianou, S. Fousas
Novel roles of vitamin D in pathogenesis of cardiovascular disease Stefania Makariou, Evangelos N Liberopoulos, Anna Challa